WuXi Biologics Constructs Dundalk Single-Use Production Facility

Published 6-15-2019

WuXi Biologics began construction in May of 2019 on a $365 million pharmaceutical production facility in Dundalk, Ireland. Sited on 52 acres, the 522,000-sf contract manufacturing center will utilize single-use technologies and processes, enabling cost-effective scale-out and the simultaneous production of multiple batches of varying volumes. Commercial operations are expected to begin in 2022 at the site, which will be the company's first manufacturing plant outside of China.